Home Newsfeeds Morgan Stanley Maintains Equal-Weight on Primerica, Lowers Price Target to $132

Morgan Stanley Maintains Equal-Weight on Primerica, Lowers Price Target to $132

Morgan Stanley analyst Bob Huang maintains Primerica (NYSE:PRI) with a Equal-Weight and lowers the price target from $148 to $132.

byBenzinga Newsdesk

July 6, 2022

1 minute read

Morgan Stanley analyst Bob Huang maintains Primerica (NYSE:PRI) with a Equal-Weight and lowers the price target from $148 to $132.

What’s Going On With Rivian Automotive Stock Today?

By Nabaparna Bhattacharya

April 12, 7:36 AM

Rivian Automotive's stock is trading lower in premarket as it prepares to announce first-quarter financial results next month amid a year of cost-cutting measures and production adjustments.

ACES

Ecolab Q2 EPS $1.10 Beats $1.09 Estimate, Sales $3.58B Beat $3.51B Estimate

By Bill Haddad

July 26, 8:31 AM

Ecolab (NYSE:ECL) reported quarterly earnings of $1.10 per share which beat the analyst consensus estimate of $1.09 by 0.92 percent. This is a 9.84 percent decrease over earnings of $1.22 per share from the same period

ECL

Inhibrx Announces Updated Efficacy And Safety Data From The Expansion Cohorts In The Phase 1 Trial Of INBRX-109 For The Treatment Of Chondrosarcoma

By Benzinga Newsdesk

November 16, 10:02 AM

Inhibrx, Inc. (NASDAQ:INBX), a clinical-stage biopharmaceutical company dedicated to the development of therapeutics for oncology and rare diseases, today announced updated efficacy and safety data from the ongoing

INBX

American Airlines Pilot Contract Offer Increases To $9 Billion Following United Agreement

By Bibhu Pattnaik

July 23, 10:33 AM

American Airlines Group Inc (NASDAQ: AAL) has agreed to increase its pilot contract offer by over a billion dollars, aligning it with a tentative agreement reached by c

AAL

Morgan Stanley Maintains Equal-Weight on Primerica, Lowers Price Target to $132

Related Posts

What’s Going On With Rivian Automotive Stock Today?

Ecolab Q2 EPS $1.10 Beats $1.09 Estimate, Sales $3.58B Beat $3.51B Estimate

Inhibrx Announces Updated Efficacy And Safety Data From The Expansion Cohorts In The Phase 1 Trial Of INBRX-109 For The Treatment Of Chondrosarcoma

American Airlines Pilot Contract Offer Increases To $9 Billion Following United Agreement